A Rapid, Blood RNA Assay for the Diagnosis of Acute Respiratory Infections

Award Information
Agency:
Department of Health and Human Services
Branch:
N/A
Amount:
$150,000.00
Award Year:
2013
Program:
SBIR
Phase:
Phase I
Contract:
1R43IP000846-01
Agency Tracking Number:
R43IP000846
Solicitation Year:
2013
Solicitation Topic Code:
NCIRD
Solicitation Number:
PA12-088
Small Business Information
VIRTICI, LLC
VIRTICI, LLC, 1124 COLUMBIA ST, STE 662, SEATTLE, WA, 98104-2050
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
079131782
Principal Investigator
 . .
 (206) 228-1458
 nfanger@virtici.com
Business Contact
 NEIL FANGER
Phone: (206) 228-1458
Email: nfanger@virtici.com
Research Institution
 Stub
Abstract
DESCRIPTION (provided by applicant): Acute respiratory infections (ARIs) represent a major cause of morbidity and mortality in the world1. About 20% of all deaths in children younger than 5 years of age are due to ARIs, with among those 90% attributed to pneumonia. This translates into approximately 150 million cases of pneumonia, with between 11-20 million children hospitalized, and more than 2 million dying from the disease (WHO). Even in the US, influenza and pneumonia are the eighth leading cause of death, the majority of which are infants and the elderly (American Lung Association). The ability to identify etiological agents of respiratory infections remains inadequate. Indeed, there are major obstacles: 1) bacteria and viruses are not always present insamples; 2) determination of infectious agent can take days; and 3) multiple tests are often required to determine source. Moreover, current tests for diagnosis are poor at assessing disease severity and, to date, only a few studies have examined the usefulness of biomarker panels that might prove beneficial in the differentiation between bacterial and viral respiratory tract infections2. Such diagnostic obstacles can delay initiation o appropriate therapy, resulting in unnecessary morbidity, death, and healthcare costs3. Rapid advances in genomics research can be leveraged to dramatically improve the management of ARIs. Recently, we developed modular analysis approaches to evaluate whole genome blood microarray profiles from 410 samples comprised of patients clinically diagnosed with ARIs and healthy controls. The meta-analysis identified 10 gene sets (or modules) that were able to discriminate between bacterial and viral agents responsible for ARIs with high accuracy. Our goal is to develop AResT (Acute Respiratory-related Transcripts), an innovative multivariate RNA assay designed for rapid triage of patients with ARIs. The first step in the development process is to reduce the current number of transcript targets within these 10 modules (n=694) while enabling the use of a PCR-based detection method, and improve the scoring algorithm against an independent set of blood samples from patients diagnosed with well-characterized ARIs. The specific aims are to: 1) validate a PCR-based multivariate RNA profiling assay using banked patient samples; 2) improve the scoring algorithm while determining the minimum probe set; and 3) compare AResT test accuracy against commonly used blood biomarkers PCT and CRP. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE:Acute respiratory infections (ARIs) are the eighth leading cause of death in the US. Currently, there is no single diagnostic assay that can rapidly discriminate between viral- and bacterial-induced ARIs, resulting in inadequate decision support tools forphysicians, unnecessary or delayed use of antibiotics, and increased morbidity and mortality. This project aims to develop a blood test that uses a patient's blood transcript profile to identify the etiological agents of ARIs, improving the management ofthis disease in children worldwide.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government